Corvus Pharmaceuticals (CRVS) Cash & Current Investments (2015 - 2026)

Corvus Pharmaceuticals' Cash & Current Investments history runs 12 years deep, the most recent figure standing at $236.7 million for Q1 2026.

• In Q1 2026, Cash & Current Investments rose 4635.23% year-over-year to $236.7 million; the TTM figure through Mar 2026 stood at $236.7 million (up 4635.23% YoY), while the FY2025 annual figure was $56.8 million, up 9.21% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $236.7 million, up from $56.8 million in the prior quarter.
• The five-year high for Cash & Current Investments was $236.7 million in Q1 2026, with the low at $2.9 million in Q3 2025.
• The 5-year median for Cash & Current Investments is $14.7 million (2025), against an average of $31.9 million.
• The sharpest annual moves came in 2022 and 2026: Cash & Current Investments plunged 79.26% in 2022, then surged 4635.23% in 2026.
• Corvus Pharmaceuticals' Cash & Current Investments stood at $13.2 million in 2022, then retreated by 4.1% to $12.6 million in 2023, then jumped by 311.76% to $52.0 million in 2024, then gained by 9.21% to $56.8 million in 2025, then soared by 317.12% to $236.7 million in 2026.
• Business Quant data shows CRVS's Cash & Current Investments at $236.7 million in Q1 2026, $56.8 million in Q4 2025, and $2.9 million in Q3 2025.